Research looks at saxagliptin's safety, efficacy in diabetes

09/3/2013 | HealthDay News

Type 2 diabetes patients who took saxagliptin did not have a higher risk of heart attack, stroke or cardiovascular death than those who took a placebo pill, a study in the New England Journal of Medicine indicated. Researchers also found patients in the saxagliptin arm attained better glucose control and reduced insulin therapy requirements. However, researchers noted an increased rate of hospitalization for heart failure among saxagliptin-treated patients, which merits further evaluation.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC